Empagliflozin preserves cardiac function and modulates metabolism in a mouse model of Duchenne muscular dystrophy
Duchenne muscular dystrophy (DMD) is a fatal genetic disorder characterized by skeletal muscle degeneration and cardiomyopathy. Effective cardiac therapies remain limited. This study investigated the therapeutic potential of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (EMPA) in the dystrophin-deficient DBA2/J- mdx mouse model of DMD. Male mice received control chow or EMPA-containing chow (~25mg/kg/day), and cardiac function was evaluated longitudinally using four-dimensional ultrasound imaging. EMPA did not alter left ventricular mass or volume but delayed the onset of systolic dysfunction, preserving ejection fraction (EF) for 12 weeks and maintaining significantly higher EF through 24 weeks. EMPA also attenuated progressive impairments in systolic and diastolic myocardial deformation. Functional preservation was accompanied by reduced cardiomyocyte hypertrophy and reduced expression of cardiac stress genes. EMPA increased mtDNA copy number, reduced mtDNA damage, preserved the mtDNA-encoded respiratory chain protein MT-CO1, and increased myocardial ATP content, supporting improved mitochondrial integrity and myocardial energetic capacity. In addition, EMPA induced transcriptional changes consistent with enhanced fatty acid and ketone metabolism. Systemically, EMPA improved growth trajectory, preserved relative lean mass, increased skeletal muscle torque, attenuated fiber-type remodeling, and did not adversely affect renal function. Together, these findings support SGLT2 inhibitors as a promising therapeutic strategy for DMD-associated cardiomyopathy.
Authors
- Carol A. Witczak (ORCID: https://orcid.org/0000-0003-4165-4740)
- Meena S. Madhur (ORCID: https://orcid.org/0000-0002-0407-634X)
- Steven S. Welc (ORCID: https://orcid.org/0000-0002-2353-0325)
- Akanksha Agrawal (ORCID: https://orcid.org/0000-0003-2564-4999)
- Linda A. Bean (ORCID: https://orcid.org/0000-0003-3631-2850)
- Joshua R. Huot (ORCID: https://orcid.org/0000-0002-8632-5791)
- Li‐Fan Zeng (ORCID: https://orcid.org/0000-0002-3173-2744)
- Craig J. Goergen (ORCID: https://orcid.org/0000-0001-8883-7953)
- Areli Jannes S. Javier (ORCID: https://orcid.org/0000-0002-9056-9887)
- Conner C. Earl (ORCID: https://orcid.org/0000-0002-7916-3165)
- Larry Wayne Markham (ORCID: https://orcid.org/0000-0002-2804-4641)
- John P. Salvas (ORCID: https://orcid.org/0000-0003-1550-8758)
- Il‐man Kim (ORCID: https://orcid.org/0000-0002-9268-8337)
- Mark C. Kowala
- B. Zeidler
- Connor R Thomas
- Alyssa M. Richards
- Niharika Narra
- Lifan Zeng
Institutions
- Indiana University Health (US)
- Purdue University West Lafayette (US)
- Indiana University Indianapolis (US)
- Indiana University School of Medicine (US)
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- JCI Insight
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1172/jci.insight.206796
- Citations
- 1
- Primary Topic
- Cardiovascular Function and Risk Factors
- Type
- article
- Field-Weighted Citation Impact
- 2.91
Funders
- Purdue University
- Riley Children's Foundation
- National Institutes of Health
- School of Medicine, Indiana University
- National Heart, Lung, and Blood Institute
- National Institute of Arthritis and Musculoskeletal and Skin Diseases